Truist Securities analyst Robyn Karnauskas raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $128.00 (from $127.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE